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Abstract
This study investigated the microbiological characteristics of 100 clinical isolates of Cryptococcus neoformans species complex, including
serotypes, mating types, molecular types, antifungal susceptibility and virulence. The isolates were collected at National Taiwan Uni-
versity Hospital from 1999 to 2004. Eight isolates of C. neoformans from pigeon droppings were also evaluated. Among these isolates,
99 were C. neoformans var. grubii serotype A and one was C. neoformans var. gattii serotype B. All of these isolates were a mating
types. PCR ﬁngerprinting, generated by primers M13 and (GACA)4, and URA5 gene restriction fragment length polymorphism analysis
revealed that C. neoformans var. grubii isolates belonged to the VNI (98 isolates) and the VNII (one isolate) types, and the single
C. neoformans var. gattii was VGI type. The similar proﬁles of clinical and environmental isolates suggest that patients might acquire
these yeasts from the environment. The MIC90 for ﬂuconazole, itraconazole, 5-ﬂucytosine, voriconazole and amphotericin B against
all C. neoformans isolates were 8, 0.5, 4, 0.125 and 0.5 mg/L, respectively. All clinical isolates produced urease, phospholipase, capsule
and melanin, but these activities varied with individual isolates. Analysis of six clinical and two environmental isolates with various lev-
els of phospholipase activity indicated a correlation between phospholipase activity and the ability to adhere to the lung epithelial cell
line, A549. The extent of cell damage, as indicated by lactate dehydrogenase release, also paralleled the phospholipase activity of
these isolates. In addition, production of melanin contributed signiﬁcant protection against amphotericin B killing of the isolates
tested.
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Cryptococcus neoformans is an encapsulated, ubiquitous envi-
ronmental yeast that causes cryptococcosis, a potentially
serious disease that affects healthy and immunocompromised
individuals, especially patients with AIDS [1]. The aetiological
agent of cryptococcosis is classiﬁed into two species [2];
they are C. gattii (serotypes B and C) and C. neoformans, with
two varieties: C. neoformans var. grubii (serotype A) [3] and
C. neoformans var. neoformans (serotype D) [4,5] as well as
an AD hybrid [1]. These species and varieties may have dif-
ferent ecological characteristics, as well as a different epide-
miology and pathogenicity [6–8].
Cryptococcus neoformans is a heterothallic basidiomycetous
yeast with a sexual cycle involving mating between haploid
MATa and MATa cells [4,9]. MATa strains have been shown
to be much more common and more virulent than congenic
MATa strains [10,11].
PCR ﬁngerprinting based on M13 DNA has identiﬁed two
major genotypes (VNI and VNII) among the strains of sero-
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
type A, the VNI genotypes being the most commonly found
worldwide [12,13].
Amphotericin B, alone or combined with 5-ﬂucytosine
and azoles, including ﬂuconazole, itraconazole or voriconaz-
ole, has been the treatment of choice for cryptococcal
infections, although alternative agents with activities against
C. neoformans have recently become available [14]. Periodic
surveillance in Taiwan hospitals is needed to monitor
trends of resistance to commonly used antifungal agents
including amphotericin B and azoles within C. neoformans
[15,16].
Several factors have been identiﬁed that contribute to the
virulence of C. neoformans strains. Among the best character-
ized are the presence of a capsule, and the production of
melanin, urease and phospholipase [1,17–19]. Studies of
cryptococcosis in animal models infected with different
strains of C. neoformans have indicated that there is consider-
able variation in the virulence of individual isolates [20,21].
Blackstock et al. [21] showed that the more virulent isolates
had higher expression of several virulence factors. Although
secretory phospholipase has been demonstrated to be a
virulence factor for C. neoformans [19,22–24], no conclusive
correlations were made between virulence and phospholi-
pase activities in clinical isolates [5,20,25,26].
The purposes of this study were: (i) to identify the sero-
types; (ii) to identify the mating type; (iii) to assess the anti-
fungal susceptibility; (iv) to identify the genotypes; (v) to
analyse virulence factors in C. neoformans isolates, and




One hundred randomly selected, consecutive, and non-
duplicate clinical isolates from patients admitted to NTUH,
a 2000-bed teaching hospital in northern Taiwan, and eight
environmental isolates (E1-E8 from pigeon guano in Taipei)
of C. neoformans collected between 1999 and 2004 were
studied. All clinical isolates were recovered from patients
with clinically signiﬁcant infections, including meningitis,
cryptococcaemia, and pneumonia. These isolates were iden-
tiﬁed to the species level by conventional methods, based
on growth appearance on Sabouraud dextrose agar (SDA;
Becton Dickinson, Franklin Lakes, NJ, USA) at 37C, assimi-
lation of carbohydrates, production of urease, and the pres-
ence of a capsule [27] and conﬁrmed using the API 20C
and Vitek YBC systems (bioMerieux Vitek, St Louis, MO,
USA). L-canavanine-glycine-bromothymol blue (CGB) agar
was used to screen for C. gattii. Reference strains, ATCC
90112 (serotype A), ATCC 32269 (serotype B), ATCC
34873 (serotype D), ATCC 32608 (serotype C), H99
(serotype A, a mating type) [11] and KN99a (serotype A, a
mating type) [11] were included in individual assays for
comparison, when needed.
DNA isolation
Genomic DNA was prepared using a commercial kit
(PureGene Yeast and Gram Positive DNA Isolation Kit;
Minneapolis, MN, USA) following the manufacturer’s
protocol [28].
Molecular identiﬁcation of serotypes
CAP59 gene restriction enzyme analysis (CAP59-REA) [29]
and multiplex PCR using six primers for the LAC1 gene and
the CAP64 gene [30] were performed to differentiate the
serotypes of C. neoformans.
Determination of mating types by PCR
PCR using primer pairs, speciﬁc for mating type a (MATa1–
MATa2) and a (MATa1–MATa2), respectively, were
performed [5]. Cryptococcus neoformans H99 (serotype A,
MATa) and C. neoformans KN99a (serotype A, MATa) were
used as positive controls.
Genotyping by PCR ﬁngerprinting and URA5 gene
restriction fragment length polymorphism analysis
Oligonucleotides of the minisatellite-speciﬁc sequence of
phage M13 and of the microsatellite-speciﬁc sequence
(GACA)4 were used as single primers in the PCR ﬁngerprint-
ing reactions [13]. URA5 gene restriction fragment length
polymorphism (RFLP) analysis was performed as described
[12].
Antifungal susceptibility testing
Antifungal susceptibility testing of C. neoformans isolates was
performed according to the protocol described in the
NCCLS document M27-A2 [31]. The following antifungal
agents were used: ﬂuconazole and voriconazole (Pﬁzer, Inc.,
New York, NY, USA), itraconazole (Janssen, Titusville, NJ,
USA), ﬂucytosine (Sigma Chemical Co., St Louis, MO, USA),
and amphotericin B (Bristol-Myers Squibb, Princeton, NJ,
USA). The tested concentrations of these agents ranged
from 0.03 to 64 lg/mL. Cryptococcus neoformans ATCC
90112 was used as the control.
In vitro melanin production
Cryptococcus neoformans cells were grown on SDA medium
at 37C for 2 days. Cell suspension was made equivalent to
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4 McFarland standard scale (c. 5 · 106 cells/mL) and 3 lL
was inoculated onto the minimal medium agar plates with
the addition of 1 mM L-dopa [32]. After incubation at 37C
for 7 days, the extent of brown pigment formation in each
spot was graded as 1+ to 4+ indicating the increased
pigment production.
Urease activity
Cell suspension at McFarland 2 standard scale was prepared as
described above. One hundred microlitres were inoculated
onto the Christensen’s agar slant to test for urease activity
[18]. Activity was graded as 1+ to 3+ indicating the increased
pink colour intensity after incubation at 37C for 24 h.
Phospholipase activity
Each sample was examined for extracellular phospholipase
production by the method of Chen et al. [25]. The ratio of
the diameter of the colony to the total diameter of the col-
ony plus precipitation zone (Pz) was measured as an index of
phospholipase activity. A Pz value of 1.0 indicated that the
test sample was phospholipase negative.
Adherence to A549 cells
Adhesion assays were performed as described [20] with
some modiﬁcations. Cells of the A549 human lung epithelial
line were grown to conﬂuence (104 cells/well) in 96-well
plates in RPMI 1640 medium (Gibco, Gaithersburg, MD,
USA) supplemented with 10% fetal bovine serum (FBS).
A549 monolayers were washed with Hank’s balanced salts
(Gibco) containing 5% FBS (HBS–FBS). Yeast cells were
grown overnight in Sabouraud Dextrose Broth at 37C,
washed with phosphate-buffered saline (PBS) and resus-
pended in RPMI 1640 medium to generate a ratio of 20 yeast
cells per host cell. After co-incubation at 37C in a CO2
incubator for 6 h, non-adherent fungi were removed by
washing with HBS–FBS. A549 cells were then trypsinized,
lysed with water and the resulting suspension plated onto
SDA plates. Colonies were counted after incubation for
48 h. Adherence was calculated as a percentage of the origi-
nal inoculum recovered. All experiments were performed in
triplicate sets and statistically analysed using Student’s t-tests.
For microscopic observation, after removal of non-adherent
fungi by washing, the cells were trypsinized (0.05%), washed
again with PBS, resuspended in HBS–FBS and cytospun onto
slides [33]. Interaction between A549 cells and fungi was
observed by microscopy after Gram staining. A549 cells
were unable to kill cryptococci, which was concluded from
the observation that no signiﬁcant differences in the number
of viable yeasts were found before and after exposure to
A549 cells.
Analysis of host cell damage by lactate dehydrogenase assay
To evaluate host cell damage induced by the presence of
C. neoformans, conﬂuent A549 cells were incubated with
cryptococci for 24 h under the conditions described above.
After incubation, supernatants were collected, centrifuged
for removal of yeast cells and assayed for the release of
lactate dehydrogenase (LDH) by the LDH assay kit (Cyto-
Tox 96 Non-radioactive Cytotoxicity Assay; Promega,
Madison, WI, USA) [34]. All experiments were performed
in triplicate sets and statistically analysed using Student’s
t-tests.
Amphotericin B killing assay
Melanization was induced by growing yeast cells on deﬁned
minimal medium agar plates with 1 mM L-dopa for 7 days
as described above [35]. Melanized or non-melanized yeast
cells were suspended in normal saline at a density of
2 · 103 cells/mL. Cell counts were determined with a haem-
ocytometer. Microcentrifuge tubes containing 0.1-mL aliquots
of an antifungal at ten times the ﬁnal concentration were
inoculated with 0.9 mL of the yeast suspensions. After incu-
bation at 37C for 2 h, aliquots were plated on SDA to
determine their survival as measured by determination of
the number of CFUs. The survival rate was compared with
that of fungal cells incubated in PBS.
Results
Patients
Men predominated (male 74% vs. female 26%) among the
100 patients (Table 1). The majority of isolates were from
cerebrospinal ﬂuid (n = 43), followed by blood (n = 40)
and pleural effusion (n = 6). Other specimens included
bronchial washing (n = 2), bronchoalveolar lavage (n = 3),
lung abscess (n = 1), sputum (n = 3), surgical wound
(n = 1) and throat swab (n = 1). Forty-one patients had
underlying diseases, including 27 patients with AIDS and
14 with other diseases, including acute lymphoblastic leu-
kaemia (n = 1), adult T-cell leukaemia (n = 1), chronic lym-
phocytic leukaemia (n = 1), non-small cell lung cancer
(n = 1), cervical cancer (n = 1), melanoma (n = 1), end-
stage renal disease (n = 2), and systemic lupus erythemato-
sus (n = 4).
Serotypes and genotypes
Among the 100 clinical isolates tested, 99 isolates were sero-
type A and one was serotype B (example proﬁles in
Fig. 1a,b), which tested positive on the CGB plate. M13 PCR
ﬁngerprinting and URA5-RFLP typing were used to investigate
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the genetic diversity and relationships among the isolates.
We found that the single var. gattii isolate (CB) belonged to
the VGI genotype and the var. grubii serotype A isolates
exhibited VNI (98 isolates) and VNII (one isolate, C9) pat-
terns (example proﬁles in Fig. 2a,b). All eight environmental
isolates were serotype A and belonged to VNI (example
proﬁles in Figs 1a and 2a,c). Fig. 2c shows the represent-
ative (GACA)4 ﬁngerprinting of two clinical and four
environmental isolates with the patterns of serotypes A, B,
C and D reference strains shown in parallel.
Mating types
Direct PCR of MATa and MATa pheromones revealed that
all clinical and environmental isolates were positive for
MATa as indicated by a 101-bp PCR product.
Antifungal susceptibility testing
In vitro susceptibility testing of all clinical isolates of C. neofor-
mans to amphotericin B, ﬂucytosine, ﬂuconazole, itraconazole
and voriconazole was performed. The MIC90s and MIC50s for
ﬂuconazole, itraconazole, 5-ﬂucytosine, voriconazole and
amphotericin B were 8, 0.5, 4, 0.125 and 0.5 mg/L, and 2,
0.25, 1, 0.06 and 0.25 mg/L, respectively.
Virulence
We examined differences in the production of melanin and
the activities of phospholipase and urease in these isolates.
The expression of these three virulence traits was highly
divergent among the isolates. Whereas 97 isolates
expressed intermediate to high phospholipase activity, ure-
ase activities were low to intermediate in 77 isolates and
the level of melanin production was low to intermediate in
89 isolates (Table 1). All isolates could produce capsules
(data not shown), but there was no signiﬁcant correlation
of capsule size with any of the three virulence traits. The
intermediate to high expression of phospholipase but not
urease activity or melanin production among these clinical
isolates implies that phospholipase may contribute to the
virulence of these isolates. In order to investigate further
the role of phospholipase in these isolates, we performed
adhesion assays using the high and the low phospholipase-
producing isolates (the growth rate of all isolates was com-
parable and RT-PCR was used to conﬁrm the level of phos-
pholipase expression). Fig. 3a shows that adherence of the
low phospholipase-producing isolates to the A549 cells was
about half that of the high phospholipase-producing isolates,
whereas adhesion of the two environmental isolates was
intermediate between the low and high phospholipase-pro-
ducing isolates. Light microscopy of adhesion between
C. neoformans and the A549 cells after trypsin treatment
showed that more cells of the high phospholipase-producing
isolate were associated with A539 cells compared with the
low phospholipase-producing isolate (Fig. 3c), reconﬁrming
the importance of phospholipase activity in adherence to
the A549 cells. Interaction of high phospholipase-producing
C. neoformans with A549 cells also resulted in signiﬁcant
A549 cell damage compared with the low phospholipase-
producing isolates (Fig. 3b).
Amphotericin B killing assay of melanized and
non-melanized cells
We evaluated the effect of melanin production on the
survival of clinical C. neoformans isolates after amphotericin B
exposure. As shown in Fig. 4, melanized cells were signiﬁ-
cantly less susceptible to amphotericin B than non-melanized
cells at the drug concentrations of 0.5 and 0.25 mg/L.
TABLE 1. Characteristics of Cryptococcus neoformans iso-
lates tested in this study, including host patient, sources,
serotypes, mating types, molecular types, melanin produc-












Bronchial washing 2 (2)
Bronchoalveolar lavage 3 (3)
Cerebrospinal ﬂuid 43 (43)
Lung abscess 1 (1)
Pleural effusion 6 (6)
Sputum 3 (3)
Surgical wound 1 (1)
Throat swab 1 (1)






A 99 (99) 8 (100)
B 1 (1) 0 (0)
Mating types
a 100 (100) 8 (100)
a 0 (0) 0 (0)
Molecular types
VNIa (VN6b) 98 (98) 8 (100)
VNIIa 1 (1) 0 (0)
VGIa 1 (1) 0 (0)
Pz (phospholipase activity)
0.26–0.5 (high) 59 (59) 0 (0)
0.51–0.75 (intermediate) 38 (38) 5 (62.5)
0.75–1 (low) 3 (3) 3 (37.5)
Melanin production
4+ 4 (4) 0 (0)
3+ 7 (7) 0 (0)
2+ 36 (36) 4 (50)
1+ 53 (53) 4 (50)
Urease activity
3+ 23 (23) 0 (0)
2+ 26 (26) 3 (37.5)
1+ 51 (51) 5 (62.5)
aBy PCR ﬁngerprinting using M13 primer and URA5-RFLP.
bBy PCR ﬁngerprinting using (GACA)4 primer.
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Discussion
Cryptococcosis is one of the most prevalent and serious
mycoses. In Taiwan, only a few sporadic studies of C. neofor-
mans have been reported [15,16,36]. In this study, we add
important information about the characteristics of C. neofor-
mans isolates from northern Taiwan. We found that 99% of
clinical isolates were var. grubii serotpe A. This ﬁnding is
consistent with previous studies worldwide, which found that
var. grubii is the most prevalent cryptococcal isolate
[5,12,13,37,38]. The low incidence of var. gattii compared
with previous reports from Taiwan [16,36] (1% vs. 35.6%
and 14.7%) may be due to the differences in patients, the
time period of sample collection and the randomness intro-
duced by including non-duplicate samples. For the ﬁrst time
in Taiwan, two molecular methods, URA5-RFLP and PCR
ﬁngerprinting using primer M13 and primer (GACA)4,
were applied simultaneously to unravel the genotypes of
C. neoformans isolates. Previous analysis of C. neoformans iso-
lates by (GACA)4 ﬁngerprinting revealed four different
groups [39]. One of them includes serotype A isolates
(VN6), another includes serotype D isolates (VN1) and the
remaining two (VN3 and VN4) include AD strains. All of our
isolates were revealed to be of the VNI (VN6) type. These
results are in agreement with studies from other countries,
(a) (b) (c)
FIG. 2. (a) Examples of URA5 gene restriction fragment proﬁles of clinical and environmental isolates of Cryptococcus neoformans. C6-C7, C9 and
CB, clinical isolates; E5-E6, environmental isolates; A, B, D, and M are as in Fig. 1. (b) Examples of PCR ﬁngerprinting patterns obtained with the
primer M13. C9, C31-C32, clinical isolates of C. neoformans; A, B, D, and M are as in Fig. 1. (c) Examples of PCR ﬁngerprinting patterns obtained
with the primer (GACA)4. C31-32, clinical isolates; E1-E4, A, B, D, M are as in Fig.1; C, ATCC 32608, serotype C.
(a) (b)
FIG. 1. (a) Agarose gel electrophoresis of the CAP59 gene restriction proﬁles of Cryptococcus neoformans serotypes. Upper panel, BsmFI-
restricted proﬁle; lower panel, HpaII-restricted proﬁle. C1–C4, serotype A clinical isolates; E1-E4, environmental isolates; CB, serotype B clinical
isolate; A, ATCC 90112, serotype A; B, ATCC 32269, serotype B; D, ATCC 34873, serotype D; M, 100-bp marker. (b) Ampliﬁed fragments of
isolates obtained in multiplex PCR with the primers for LAC1 and CAP64. C1-C6, serotype A clinical isolates; A, B, D and M are as in (a).
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which reported that VNI is the most common molecular
type among C. neoformans isolates [5,12,13,37,38].
We found that expression of the various virulence traits
was not correlated with each other. This is similar to a
study by Clancy et al. [20], who found no correlation
among capsule size, phospholipase activities and melanin
formation. These results suggest that host factors contrib-
ute signiﬁcantly to the pathogenesis of C. neoformans. Inter-
estingly, we found three lines of evidence that suggest that
phospholipase activity is an important causative factor of
cryptococcosis. First, the majority of isolates exhibited high
phospholipase activity instead of urease or melanin produc-
tion. Second, high phospholipase activity was correlated
with increased adherence to lung epithelial A549 cells.
Third, cell damage indicated by LDH release was more
frequent in the high phospholipase-producing isolates. Fur-
ther fungal–macrophage interaction assay and animal exper-
iments are needed to conﬁrm the importance of
phospholipase.
Previous studies have revealed that melanin affects the
susceptibility of C. neoformans to certain compounds, such
as amphotericin B [40,41]. It has been suggested that cryp-
tococcal melanin deposited in the cell wall appears to
capture drugs, preventing them from reaching their active






FIG. 3. Adhesion of phospholipase-producing Cryptococcus neoformans to A549 cells. (a) C24, 42, 45, low producers; C52, 59, 95, high produc-
ers; E7, 8, environmental isolates. The Pz value is shown above each bar. Results obtained for C59 cells were deﬁned as 100%. The data are
averages and standard deviations of three independent experiments. a, b signiﬁcantly different from c (p <0.01, by Student’s t test). (b) Lactate
dehydrogenase (LDH) release of A549 cells after interaction with phospholipase-producing C. neoformans. C24, 42, 45, 52, 59, 95, E7-8, are as in
(a). Supernatants, after incubation, were assayed for LDH release using colorimetry described in Materials and Methods. Data are expressed as a
percentage of LDH release from unstimulated cells treated with Triton X-100 and represent the mean ± SD of triplicate measurements from
two independent experiments. Control, medium only background. a vs. b, p <0.01 by Student’s t test. (c) Light microscopy of C. neoformans
adhering to A549 cells. A549 cells were stimulated for 6 h at 37C with low (C24) or high (C59) phospholipase-producing isolates of C. neofor-
mans, followed by washing, trypsinization, cytospin to slides and observation. a, no yeast control, 400·; b, A549 incubated with C59, 400·; c,
A549 incubated with C24, 400·; d, A549 incubated with C59, 650·. Data are representative of three independent experiments.
FIG. 4 Amphotericin B killing assay of melanized and non-melanized
Cryptococcus neoformans. The survival rates of melanized vs. non-mel-
anized yeast cells (clinical isolates, C48 and C67) after exposure to
0.25 and 0.5 mg/L of amphotericin B for 2 h were compared with
those of fungal cells incubated in phosphate-buffered saline. The data
represent averages of four independent experiments with standard
deviations. p <0.05 as determined by Student’s t test for a compari-
son between non-melanized and melanized cells.
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signiﬁcant protection against amphotericin B killing of
C. neoformans.
In conclusion, the majority of the clinical isolates in this
study belonged to var. grubii, serotype A, were mating type a
and could be grouped into the molecular type VNI. We
re-identiﬁed phospholipase as a potential virulence factor
and a cause of cryptococcosis.
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